Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

DRAXIMAGE DTPA

×

Overview

What is DRAXIMAGE DTPA?



What does DRAXIMAGE DTPA look like?



What are the available doses of DRAXIMAGE DTPA?

Kit for the preparation of Technetium Tc 99m pentetate injection: 10 mL multiple dose vials containing up to 9250 MBq / mL (250 mCi / mL) at time of preparation (reconstitution) ().

What should I talk to my health care provider before I take DRAXIMAGE DTPA?

How should I use DRAXIMAGE DTPA?

DRAXIMAGE DTPA, after radiolabeling with Technetium Tc 99m, is indicated for

Tc 99m labeled DRAXIMAGE DTPA injection is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure to the patient and healthcare worker. During preparation and handling, use water proof gloves and effective shielding, including syringe shields .


What interacts with DRAXIMAGE DTPA?

Sorry No Records found


What are the warnings of DRAXIMAGE DTPA?

Sorry No Records found


What are the precautions of DRAXIMAGE DTPA?

Sorry No Records found


What are the side effects of DRAXIMAGE DTPA?

Sorry No records found


What should I look out for while using DRAXIMAGE DTPA?

Hypersensitivity to the active ingredient or to any component of the product


What might happen if I take too much DRAXIMAGE DTPA?

Sorry No Records found


How should I store and handle DRAXIMAGE DTPA?

Store the unreconstituted reaction vials at 25°C (77°F); excursions permitted between 15 and 30°C (59 and 86°F). This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.Store the unreconstituted reaction vials at 25°C (77°F); excursions permitted between 15 and 30°C (59 and 86°F). This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.The FLECTOR PATCH is supplied in resealable envelopes, each containing 5 patches (10 cm × 14 cm), with 6 envelopes per box (NDC 68788-6396-3). Each individual patch is embossed with "FLECTOR PATCH 1.3%".


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Intravenous Administration

Aerosolized Inhalation Administration

Non-Clinical Toxicology
Hypersensitivity to the active ingredient or to any component of the product

Hypersensitivity reactions, including anaphylaxis, have been reported during post-approval diagnostic use of Technetium Tc 99m pentetate injection. Monitor all patients for hypersensitivity reactions and have access to cardiopulmonary resuscitation equipment and personnel.

The following adverse reactions have been identified post-approval. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their exact frequency or establish a causal relationship to Technetium Tc 99m pentetate exposure.

Adverse reactions are presented in decreasing order of reported frequency:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).